Biofrontera Inc. Form 8-K Summary
Filing date: October 3, 2023. Reporting periods: Fiscal years ended December 31, 2022 and 2021. The filing was submitted under Item 8.01, Other Events, and Item 9.01, Financial Statements and Exhibits.
Business Context and Reporting Period
Biofrontera Inc. retained Marcum LLP as its independent registered public accounting firm after Grant Thornton LLP resigned. Marcum reaudited the Company’s consolidated financial statements for 2022 and 2021 and issued revised financial disclosures.
The reaudited financial statements and revised MD&A are substantially identical to the materials included in the Company’s 2022 Annual Report, except for the matters described below.
Financial Metrics and Liquidity
- The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures in the supplied text.
- Marcum’s audit report includes a “going concern” paragraph and related disclosure.
- The Company stated that the reaudit was undertaken to preserve flexibility regarding potential additional financing and to provide an opportunity to continue as a going concern.
- The identified adjustments did not affect consolidated operating results, cash flows, or equity, except for changes resulting from the reverse stock split.
Material Changes Versus the Prior Comparable Period
- Marcum’s reaudited financial statements replace the previously audited 2022 and 2021 statements for presentation purposes.
- Share and related equity amounts were adjusted to reflect a one-for-20 reverse stock split effective July 3, 2023.
- Additional detail was added concerning warrant liabilities, including expenses related to a July 2022 warrant inducement.
- Other updates reflect events occurring after December 31, 2022 and before completion of the reaudit, including the legal claim described below.
- Except for these matters, the filing states that the 2022 Annual Report remains unchanged.
Outlook, Risks, Contingencies, and Unusual Items
- Going concern: The audit report and related disclosures identify substantial uncertainty regarding the Company’s ability to continue as a going concern.
- Legal claim: DUSA Pharmaceuticals, Inc. and affiliates sued Biofrontera, alleging breach of contract, Lanham Act violations, and unfair trade practices. The allegations relate to promotion of Ameluz in a manner allegedly inconsistent with its FDA-approved labeling.
- The complaint was filed in the U.S. District Court for the District of Massachusetts on or before September 13, 2023 and was subsequently transferred by agreement to the U.S. District Court for the District of New Jersey.
- Biofrontera denies the claims and intends to defend the matter vigorously. The filing does not provide an estimated potential loss or probable financial impact.
- Forward-looking statements concern regulatory review and approvals, funding availability, product development, and other future matters and are subject to material risks and uncertainties.
Key Facts for Investors to Verify
- Review Exhibits 99.1 and 99.2 for the detailed reaudited financial statements, going-concern disclosures, liquidity position, and revised MD&A.
- Verify the Company’s available cash, financing plans, debt obligations, and funding requirements.
- Assess the potential financial and operational impact of the DUSA litigation, including any subsequent developments.
- Confirm the accounting presentation of warrant liabilities and the July 2022 warrant-inducement expense.
- Reconcile all share and per-share data for the July 3, 2023 one-for-20 reverse stock split.